chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician concerning a 13 year old female with heavy periods and no known allergies who on 04/25/2002 was vaccinated with a second dose of hep A vaccine. Concomitant therapy included hormonal contraceptives and an unspecified anti-depressant. On 04/26/2002, the pt experienced intractible nausea and vomiting and stomach pain and was hospitalized for 4 days. It was noted that her vomiting was severe and she was unable to keep anything down. Her SGPT and SGOT were elevated at 100 and her bilirubin was 1.8-2.0. She was hydrated and stabilized until the 05/04/2002 when she was discharged. On 05/05/2002, she started vomiting again. Follow-up info indicated that the symptoms of nausea, vomiting and stomach pain have continued. It was reported that a fever had disappeared entirely but the "enzymes that were in the neighborhood of 100 were now 400 and 1000." It was also noted that her bilirubin was increased. It was reported that she was hospitalized on 05/01/2002 due to dehydration. On 05/06/2002, the pt came to the physician's office as was still vomiting. The doctor prescribed Zofran, Compazine and Phenergan. It was reported that the pt's condition continues. The reporter felt the pt's experience was a "temporal coincidence." The reporter felt the pt's vomiting, stomach pain, nausea, increased SGOT and SGPT and increased bilirubin were disabling. Follow up information from a physician indicated that the patient's nausea and vomiting led to dehydration and hospitalization. Her liver enzymes were elevated from May 06, 2002 to Mat 11, 2002. The recovery status was reported as unknown. The reporter felt the patient's vomiting, stomach pain, nausea, increased SGOT, increased SGPT and increased bilirubin were disabling. Additional information has been requested. Additional follow up from a physician indicated that the pt was hospitalized from 5/1/02 to 5/4/02. AFter discharge she had a recurrence of vomiting which resolved with Zofran. Her liver enzymes peaked on 5/11/02 at a 371 and 1103 for her SGOT and SGPT respectively. Susbequently, she felt better. Her last blood work on 5/20/02 showed a normal SGOT and a AGPT of 114. It was noted that she also had a viral stool culture which was negative. It was reported that the pt is improving. The reporter felt the pt's vomiting, stomach pain, nausea, increased SGOT, increased SGPT and increased bilirubin were disabling. On 9/4/02, it was reported that the pt's vomiting and described hepatitis had resolved. Liver enzymes were within normal limits on 5/28/02. All viral cultures and ANA were negative. As of 5/28/02, the pt recovered. No further info is expected.  A 15-day follow up report received 6/19/2002 adds no new info.
2 Days after shot a large bruise on my left shin appeared,  the following day another bruise same leg near my knee appeared.  Bruising is till there but getting better.
I got a bump ( lymph nodes) on my left side of my neck , the area is swollen and is painful
I felt very tired after the vaccine for a day. On 08/02/2022, I tested positive with a home test for COVID-19. I had a sore throat, runny nose, body aches but no fever. I was sick for five days but by day seven I was feeling much better. I previously tested positive for COVID-19 on 04/15/2022. I had no appetite, diarrhea, vomiting and extreme fatigue. I contacted my doctor and was given the prescription PAXLOVID. It helped but my asthma was aggravated. For two months I took prednisone to manage my asthma. I was really sick up until the end of June 2022. Now, I can't walk as fast as I once did. COVID-19 really knocked me out.
Pt presented with covid pneumonia, uncontrolled diabetes, dehydration and multiple falls. Pt given iv fluids and labs monitored. pt discharged home.
Eyes began to have a yellow/green discharge. On the morning of 01/07/2014, awoke with swollen eyes, cheeks, and lips with excessive eye discharge.
I felt fine immediately after my second vaccine;  about 12 hours later, I woke up due to the most excruciating, electric nerve pain in my right ankle - any of the slightest movement or touch caused this nearly unbearable pain.  It lasted constantly for about 6 hours (I got a little relief from keeping a heated blanket wrapped around my ankle and foot).  The extreme pain finally subsided 6 hours later, and I developed a fever between 99-100 degrees that lasted another 15 hours.  By the following morning, the fever was gone, but I still have remnants of this severe ankle pain that come and go seemingly without cause.  I have not experienced any recent injuries etc that I can associate with this.  The only thing I can think of is when I was 16 years old, this foot was run over by a car and I sustained nerve damage, for which I received extensive physical and nerve therapy that healed the injury.  I have never had any problems with this area, and certainly never this level of pain, until now.  I went to my chiropractor yesterday, but got no relief.  Tomorrow I have a physical therapy appointment;  my chiropractor encouraged me to report this incident
Pfizer-BioNTech COVID-19 Vaccine EUA  Low grade fever of 99.4, chills, tiredness, injection site pain (couldn?t raise my arm for almost 24 hours), and feeling unwell. Most of my symptoms started over 24 hours after receiving the vaccine. I took Tylenol and Motrin to help with the pain and fever and used warm compresses to my neck and injection site. I also slept a  lot. I just started feeling normal again after 2.5 days.
Moderna COVID-19 Vaccine EUA.  I had a fever of 99.5 for 2 days and diarrhea for  2 days.  Fatigue and weakness during the whole week after the vaccine.  I couldn't eat or drink for 2 days and couldn't go for my usual walk for 4 days, and even then I wore out.  No desire yet to do anything but sleep. I was diagnosed with a UTI on 03-24-2021, so am having pain from that now, too.  Haven't had one of those since 2019, so there could be some correlation  there...I just don't feel well, like I used to.
Intermittent urticaria appeared evening after administration. Fever was present before admin. of vaccine. Pt also had a (+) rapid Ag strep test on 3/20/08.
Pt to clinic for immunizations. Pt received three immunizations in left arm, after last immunization pt eyes closed and she lost consciousness for approximately 2 to 3 seconds. Pt was positioned in a semi sitting position with feet elevated on exam table with mother at side. Pt remained in clinic room for approximately 40 minutes and drank a box of juice.  Pt then received last immunization in right arm w/o incident. Pt remained in clinic for approximately 15 minutes post last immunization and stated she did not feel light headed or dizzy. Pt was allowed to leave clinic with mother.
This is a spontaneous report received from contactable reporter(s) (Pharmacist). The reporter is the patient. A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Jan2021 as dose 1, single (Lot number: EK9231), in left arm, on 22Jan2021 as dose 2, single (Lot number: EL3249), in left arm and on 09Sep2021 as dose 3 (booster), single (Lot number: 30130BA) at the age of 68 years, in right arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 04Apr2022 as dose 4 (booster), single (Lot number: 005M21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Chronic hypertension" (unspecified if ongoing); "hyperlipidemia" (unspecified if ongoing). Concomitant medication(s) included: ATORVASTATIN, start date: 02Jun2021, stop date: 06Aug2022; LOSARTAN, start date: 01Jun1996. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Additional information: Patient had no known allergies. Patient was treated with anti-viral COVID 19 Treatment Paxlovid from 07Aug2022 to 12Aug2022.; Sender's Comments: Based on available information, a possible contributory role of the subject product, BNT162b2 vaccine,  cannot be excluded for the vaccination failure and covid-19.  There is limited information provided in this report.  This case will be reassessed once additional information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
Within a few minutes, itchy in face (cheeks, ears, neck, nose), followed by scalp, torso, thighs, calves and soles of feet, slight tight throat, scattered small number of hives (on nose, cheek, torso).
immediately following administration of Pneumovax, patient became flushed and reported a racing heart and chest tightness.  She described it as "like receiving an aminophylline shot".  The patient was given 25mg of liquid Benadryl.  She was observed for 30 minutes until her symptoms resolved completely.  The patient was told to follow up with her physician and to report to the ER if symptoms recur.
Patient previously received full series of Moderna vaccine. Presented to the pharmacy for a booster dose. Was given Pfizer in error. As of 08-23-21, patient reports no adverse health/medical events.
Post vaccination:  patient reports nausea/dizziness, and tingling of the fingers. Patient was sent for observation at 10:30am Pulse 84 BP 94/62 RESP 18. Patient reports feeling better and released from facility by self.
Arexvy was administered when she was 36 weeks pregnant; Arexvy is not approved for patients under 60 years old; Patient was given Arexvy instead of Abrysvo; This non-serious retrospective pregnancy case was reported by a consumer via call center representative and described the occurrence of inappropriate age at vaccine administration in a 35-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On 19-SEP-2023, the patient received Arexvy. On 19-SEP-2023, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: Arexvy is not approved for patients under 60 years old) and wrong vaccine administered (Verbatim: Patient was given Arexvy instead of Abrysvo). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Arexvy was administered when she was 36 weeks pregnant). The outcome of the inappropriate age at vaccine administration, wrong vaccine administered and vaccine exposure during pregnancy were unknown.   Pregnancy exposure: Pregnancy Exposure (Arexvy): To mother in third trimester  Pregnancy Details (Neonate 1):  Pregnancy Outcome: Live neonate with no apparent congenital anomaly Delivery Notes: patient gave birth at 39 weeks   Additional Information: GSK Receipt Date: 10-OCT-2023 The patient was self-reported this case. The patient was received Arexvy vaccine instead of Abrysvo when she was 36 weeks pregnant, which led to wrong vaccine administered and vaccine exposure during pregnancy. The patient gave birth a week ago at 39 weeks. The patient received Arexvy who was younger than the indicated age which led to inappropriate age at vaccine administration. The reporter consented to follow up.
muscle stiffness; severe shivering; fever; aches and pains; This case was reported by a consumer via call center representative and described the occurrence of muscle stiffness in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   In April 2019, the patient received the 1st dose of Shingrix. In April 2019, 10 hrs after receiving Shingrix, the patient experienced muscle stiffness, shivering, fever and pain. On an unknown date, the outcome of the muscle stiffness, shivering, fever and pain were unknown.   It was unknown if the reporter considered the muscle stiffness, shivering, fever and pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient had severe muscle stiffness about 10 hours after vaccination which was tolerable. A few hours after vaccination patient experienced severe shivering, fever, and aches. The patient was afraid to have a 2nd injection because of more severe reaction. The patient asked is there anything to prevent a repeat of reactions. The patient also asked do I have a slight immunity to shingles with one injection. The patient stated that, I had a bad reaction with the first injection, am I more or less likely to have a repeat reaction.
After receiving vaccine patient developed some pain and swelling. The swelling and pain didn't go away after 7 days. Patient complains the area of the swollen is red, hard, painful, and itchy.  It's like a lumb that's about 7cm. Per patient the itchiness starts one day ago. Patient was hoping the swollen and pain will go away after 7 days but patient feels like the vaccinated area is getting worse. Patient will wait a few more days to see if the area will get better, if not patient will go see her primary care provider.
About 16 hours after I received the 2nd dose of the vaccine, I started feeling feverish, fatigued, experienced muscle weakness. This got progressively worse and peaked around 22-24 hrs after the vaccine where I had a 101.7 fever, headache, and higher degree of muscle achiness/weakness and fatigue. I took a ibuprofen and about an hour after that, the symptoms improved significantly. Aside from mild fatigue, the symptoms resolved fully by ~29 hours after I received the dose.
Patient is a 69 y.o. female presenting with cough and shortness of air since 9/21/21. She reports she was diagnosed with COVID-19 at that time.  Initially, she had fever, body aches, congestion, loss of taste and smell, loss of appetite, fatigue, cough, shortness of air and diarrhea. Her fever, body aches, congestion and loss of taste and smell have resolved. However, she has continued to have a continuous dry cough. She becomes dyspneic and light-headed with coughing. She has been using Robitussin at home with minimal improvement. She reports continued decreased appetite. On arrival to the ED, oxygen saturations were 86% on room air, and improved to high 90s on 2L NC. She reports she is coughing less and is less dyspneic with the supplemental oxygen.   Constitutional: Positive for activity change and fatigue. Negative for chills, fever and unexpected weight change.  HENT: Negative for congestion and sore throat.   Eyes: Negative for visual disturbance.  Respiratory: Positive for cough and shortness of breath.    Acute hypoxic respiratory failure secondary to COVID-19 pneumonia Diagnosis ~9/21; vaccinated in May 2021 CXR shows bilateral patchy opacities consistent w/ COVID infection. Inflammatory markers noted to have improved after starting on dexamethasone and remdesvir. Has been having slow improvement and on discharge was able to be off oxygen supplementation w/o exertion and 1 L NC on exertion. Home oxygen is provided for home discharge. She is instructed to follow with her PCP to titrate her off home oxygen.    Discharge Disposition/Condition Disposition: Home Condition: Stable (s/sx potential problems absent or manageable)
Patient developed rash and itch on his back about 3 weeks after he received his first dose.  His dermatologist thought it could be from the shingrix
12/9/2021 - Sent to ER from Oncology for SOB/hypoxia and immunocompromised due to 3/5 chemo completed for stage IV lung Ca. POC Covid test positive. On arrival temp 37, RR 18, SpO2 94 on supp O2, BP 131/87, WBC 7.7. Chest xray revealed bilateral infiltrates concerning for Covid 19. Admitted to Telemetry for covid pneumonia.  Started on Vancomycin, Cefepime, Decadron, Lovenox, and Remdesivir. 12/10 -  Baricitinib added to treatment. On high flow NC for O2, FiO2 65% with 40L flow. BP 152/95, HR 123.   12/11 - having asymptomatic runs of V tach and dissiculty swallowing. Kept NPO. O2 requirements not improving but not worsening. Changed steriod to Solu-medrol on 12/12. mech diet initiated 12/14- 5 day course Remdesivir complete. Baricitinib d/c 12/13 - WBC trending down. increasing hypoxia/HR - Hypoxia/tachycardia increasing -placed on BiPAP 100% FiO 12/15 - Decision for Palliative /comfort care vs aggressive treatment.  12/18 - Patient expired @1220.
Information has been received from a medical assistant referring to a patient of unknown age and gender. The patient's pertinent medical history and drug allergies were not reported. On an unknown date the patient was vaccinated with a dose of improperly stored PNEUMOVAX 23 (lot # L007720 with expiration date of 08-JUL-2016, dose 0.5 ml, frequency unknown, intramuscular). No adverse effects reported. Additional information has been requested.
rash underside of same arm / sore and itchy rash on the underside of same arm; very sore underside of the arm that I received the vaccine; chicken pox sore on the other arm.; This case was reported by a consumer via interactive digital media and described the occurrence of itchy rash in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced itchy rash, painful rash and vesicular rash. On an unknown date, the outcome of the itchy rash, painful rash and vesicular rash were recovered/resolved.   It was unknown if the reporter considered the itchy rash, painful rash and vesicular rash to be related to Shingrix.  Additional details were provided as follows: The patient had reported the event for himself/herself. The patient received 1st dose of shingrix. The patient experienced very sore and itchy rash on the underside of the arm that the patient received vaccine and also what looked like a chicken pox sore on the other arm. For the tolerance of 2nd dose of shingrix link case US2020AMR206588.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR206588:same reporter
Initial and follow-up information has been received from a physician and a healthcare professional concerning a 14 year old female who on 24-APR-2007, at 15:30, was vaccinated in her left arm with the third dose of GARDASIL vaccine (lot #4657617/0384U). Subsequently, during the evening after vaccination, on 24-APR-2007, at 2:00, the patient developed a half-dollar, raised welt at the injection site. The patient sought unspecified medical attention. It was reported that the welt lasted for two days. Additional information has been requested. This is in follow-up to report (s) previously submitted on 7/16/2007.   On 25-APR-2007, the following day, the patient was recovered. No additional information is expected.
In the fall 2016, she had a severe skin reaction to a flu vaccine. Redness, webbing, hot to touch, swelling with low grade fever. On 7/18/2017, follow the two above vaccines, Tdap and meningiococcal, she had severe discomfort, excessive redness, swelling the size of a tennis ball, webbing in appearance, low grade fever.
got  two vaccinations and 3 boosters for Moderna and not immunocompromised; This spontaneous case was reported by a patient and describes the occurrence of EXTRA DOSE ADMINISTERED (got  two vaccinations and 3 boosters for Moderna and not immunocompromised) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Heart disorder.   On an unknown date, the patient received fifth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form, third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form, second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced EXTRA DOSE ADMINISTERED (got  two vaccinations and 3 boosters for Moderna and not immunocompromised). At the time of the report, EXTRA DOSE ADMINISTERED (got  two vaccinations and 3 boosters for Moderna and not immunocompromised) outcome was unknown.    Concomitant medication information was not provided by the reporter. The patient was not immunocompromised. Treatment information was not provided by the reporter. Most recent FOLLOW-UP information incorporated above includes: On 11-May-2022: Non Significant Follow-up appended
positive COVID-19 test with symptoms; positive COVID-19 test with symptoms; This is a spontaneous report from a contactable consumer (patient). A 27-year-old female patient received the first dose of BNT162B2 (COVID-19 MRNA VACCINE BIONTECH, lot number EL1283) via an unspecified route of administration on left arm on 11Jan2021 15:45 at a single dose for covid-19 immunization. The patient usually has migraines. The patient's concomitant medications were reported none. The patient received the first dose Covid-19 vaccine on 11Jan2021. On 18Jan2021 she started showing symptoms. She tested positive for Covid on 20Jan2021. The health department said she can come off of quarantine on Friday, 29Jan2021. She is scheduled her second dose 01Feb2021. Should she get the vaccine or should she put to off since she tested positive. The symptoms she experienced were cough, difficulty breathing, headache. She also had nausea, sinus congestions, loss of taste and sense of smell and full body fatigue. The outcome of the event was not recovered.
contracted COVID after vaccination; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (contracted COVID after vaccination) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (contracted COVID after vaccination). At the time of the report, COVID-19 (contracted COVID after vaccination) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Contracted COVID.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       It was reported that the patient was a lady, She is staying home and was not hospitalized and was quarantined for 10 days.  Reporter was not sure about which manufacturer patient got the vaccine from and reported that it might be Pfizer due to patient being from over seas.  Concomitant and treatment medication was not reported.  This is a spontaneous case concerning  a female patient of unknown age,  with no relevant medical history, who experienced the unexpected non-serious events of Covid-19. The events occurred approximately on an unknown day after the unknown dose of mRNA-1273 COVID 19 Vaccine. The rechallenge was unknown since no information about the first dose was disclosed.  The event outcome was unknown. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report. Sender's Comments: This is a spontaneous case concerning  a female patient of unknown age,  with no relevant medical history, who experienced the unexpected non-serious events of Covid-19. The events occurred approximately on an unknown day after the unknown dose of mRNA-1273 COVID 19 Vaccine. The rechallenge was unknown since no information about the first dose was disclosed.  The event outcome was unknown. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.